Heart Disease Clinical Trials
Here are the 6 most popular medical studies for heart disease
Lifestyle Interventions for Heart Disease Risk Reduction
This trial will improve cardiovascular risk stratification, identify disparities in risk based on race and location, and evaluate mechanisms for population differences in risk. A multidisciplinary community-based intervention program will be implemented to decrease cardiovascular risk in high-risk populations.
Behavioural Intervention
Motivational Support for Physical Activity in Heart Disease
This trial is testing whether a new program called "Heart Up!" can help people with heart disease who feel hopeless. The program uses text messages to motivate patients to be more physically active. The goal is to see if this increases physical activity and reduces hopelessness.
Enrolled Subjects (PSR) for Coronary Artery Disease
This study is designed as a repository study to collect resting cardiac phase signals and subject meta data from eligible subjects using the Phase Signal Recorder (PSR) prior to coronary angiography. The repository data will be used for the purposes of research, development, optimization and testing of machine-learning algorithms developed by Analytics 4 Life.
Popular filter options for heart disease trials
CHD Clinical Trials
View 39 CHD medical studies.
Stem Cell Therapy
iPSC-CL for Congenital Heart Disease
This trial aims to test if lab-grown heart cells, made from stem cells, are safe and feasible to use to treat people with congenital heart disease. Participants must agree to testing and monitoring before and after product administration, and lifelong follow-up.
Behavioral Intervention
Peer Support Program for Women with Heart Disease
This trial will help to improve the care of women with heart disease by providing evidence about an innovative program that has the potential to improve their psychosocial well-being and reduce their risk of future cardiac events.
Usual Care with Medication Reconciliation for Heart Attack
Existing trials for the patient with coronary heart disease evaluate the interdisciplinary team dynamic where pharmacists (pharmacotherapists) provide therapeutic recommendations in the inpatient environment. To our knowledge, only other trial has evaluated the addition of a pharmacist (or nurse practitioner) in an outpatient collaborative cardiology practice and has found no benefit. However, the investigators believe that since a cardiology based pharmacist (pharmacotherapist) in the Veterans Health Administration has physical assessment skills, a shorter cycle length between appointments, and the ability to provide medication therapy management, the pharmacotherapist should be similarly successful as seen with other pharmacist based medication therapy management practices. The investigators will assess effectiveness by using the combined endpoint of blood pressure and lipid treatment. Additionally the investigators will conduct three substudies to evaluate if the pharmacist can improve all cause mortality and cardiovascular morbidity, adherence to antihypertensives, and patient satisfaction.
NAVA Ventilation for Congenital Heart Disease
This trialstudies how NAVA ventilation impacts brain and body hemodynamics in post-op cardiac surgery patients. It will compare NAVA to conventional ventilation over two periods and measure changes in heart, brain and lung function.
Tetralogy Of Fallot Clinical Trials
View 30 Tetralogy of Fallot medical studies.
NAVA Ventilation for Congenital Heart Disease
This trialstudies how NAVA ventilation impacts brain and body hemodynamics in post-op cardiac surgery patients. It will compare NAVA to conventional ventilation over two periods and measure changes in heart, brain and lung function.
Behavioral Intervention
eHealth App vs Nurse-Led Intervention for Congenital Heart Disease
This trial will compare the MyREADY Transition CHD app to a nurse-led one-time intervention in clinic to see which is more effective in preparing young adults with CHD for transfer to adult care.
Procedure
Controlled Oxygen Levels for Congenital Heart Defects
This trial is studying if different levels of oxygen exposure during and after surgery is safe for infants. There will be blood samples and ultrasounds taken. The trial has two groups- one that is the standard of care and the other is normoxia. They are testing to see if there is a difference in adverse events and in the measured partial pressure of oxygen values.
Heart Disease Clinical Trials With No Placebo
View 95 heart disease medical studies that do not have a placebo group.
Stem Cell Therapy
iPSC-CL for Congenital Heart Disease
This trial aims to test if lab-grown heart cells, made from stem cells, are safe and feasible to use to treat people with congenital heart disease. Participants must agree to testing and monitoring before and after product administration, and lifelong follow-up.
View More Heart Disease Trials
See another 67 medical studies focused on heart disease.
Frequently Asked Questions
Introduction to heart disease
What are the top hospitals conducting heart disease research?
When it comes to advancing medical knowledge and finding innovative solutions for heart disease, several hospitals are at the forefront of groundbreaking clinical trials. In Rochester, Minnesota, the Mayo Clinic leads the charge with four active trials focused on heart disease. This renowned institution has a long-standing reputation for excellence in healthcare and research. Similarly, the University of Ottawa Heart Institute in Canada is dedicated to combating heart disease through three ongoing clinical trials. Located in Ottawa's capital city, this institute brings together leading experts in cardiology who strive to improve patient outcomes.
In Edmonton, Alberta, the University of Alberta is actively contributing to our understanding and treatment of heart disease through three current clinical trials. Situated amidst Canada's stunning natural beauty, this hospital combines cutting-edge research with compassionate care. Additionally making strides in heart disease research is Banner University Medical Center in Phoenix where two ongoing clinical trials are underway. This center boasts state-of-the-art facilities and a multidisciplinary approach that ensures comprehensive patient care.
Lastly but certainly not leastly; UC Health Northern Colorado/Medical Center of the Rockies located Loveland has also committed itself towards furthering our knowledge about complications related to heart diseases by conducting two active experiments as they do their part while having no previous records regarding such undertakings before following its pledge towards pioneering efforts providing ample opportunities treating cardiovascular disorders.
These esteemed hospitals represent beacons of hope for those affected by heart disease worldwide—dedicated teams working tirelessly to find answers and develop better treatments. By participating in these innovative clinical trials, patients play an integral role in shaping future advancements that have far-reaching implications for countless lives impacted by this prevalent condition
Which are the best cities for heart disease clinical trials?
In the realm of heart disease clinical trials, several cities emerge as prominent hubs for research. New york, New York takes the lead with 10 active studies exploring a diverse range of treatments such as SAPIEN 3 THV and the utilization of a 3D model of the heart. Following closely behind are Rochester, Minnesota and Los Angeles, California, both with 6 ongoing trials investigating interventions like Edwards SAPIEN 3/SAPIEN 3 Ultra THV. Boston, Massachusetts and Chicago, Illinois also contribute to the field with their respective sets of active trials focused on advancements in heart disease management. These cities serve as invaluable centers for innovative research that holds promise for improving outcomes in individuals affected by heart disease.
Which are the top treatments for heart disease being explored in clinical trials?
Heart disease research is advancing rapidly, with several innovative treatments taking center stage in clinical trials. Leading the charge are three standout contenders:
- Daratumumab: This powerful drug has shown great promise in six active trials for heart disease, demonstrating its potential to revolutionize treatment options.
- Belantamab mafodotin: With four ongoing trials, belantamab mafodotin is making waves as a potential breakthrough therapy for heart disease.
- Lenalidomide: A well-established player in the field of medicine, lenalidomide continues to shine with three active trials dedicated to exploring its efficacy against heart disease. These cutting-edge treatments offer hope for patients and signify significant progress on the path toward improved cardiac care.
What are the most recent clinical trials for heart disease?
Exciting developments in the field of heart disease research have emerged through recent clinical trials. One such trial involves CagriSema, a potential treatment for heart disease that has reached Phase 3 of testing. Additionally, researchers are exploring the efficacy and safety of a new therapeutic approach known as "Treated" in Phase 1 trials. Another study focuses on the de-adoption of beta-blockers as a treatment option for heart disease in Phase 4 investigations. Furthermore, Sulfur Hexafluoride Lipid Type A Microspheres Suspension and NNC6019-0001 show promise in their respective phases, bolstering hopes for improved management and outcomes for individuals living with heart disease.
What heart disease clinical trials were recently completed?
Several recent clinical trials focused on advancements in treating heart disease have reached completion, showcasing the commitment of researchers to improving cardiovascular health. Notably, a trial sponsored by Boston Scientific Corporation investigated the effectiveness of a novel cardiac device and concluded recently. Additionally, a study conducted by the National Heart, Lung, and Blood Institute examined the impact of an innovative medication on reducing cardiovascular risk factors and was finalized this year. These accomplished trials represent significant strides in our understanding and treatment options for heart disease patients.